A Randomized, Parallel-arm, Double Blind, Placebo-controlled Study to Assess the Efficacy of Fampridine for Patients With Spinocerebellar Ataxia SCA27B Caused by a GAA Expansion in the FGF14 Gene

NCT07185347 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Spinocerebellar Ataxia 27B (SCA27B)

Interventions

DRUG: Fampridine 10 mg prolonged-release tablet (per os)
DRUG: Placebo (tablets per os)

Sponsor

Assistance Publique - Hôpitaux de Paris